December 23, 2011 -- Beijing Double-Crane Pharma announced a small acquisition, saying it will pay 110 million RMB ($17.4 million) to buy Henan Shuanghe Huali Pharma. The purchase will increase Double-Crane’s market share in transfusion products. Huali makes large volume injections, granular formulations and hard capsules. More details....
Stock Symbol: (SHA: 600062)
